Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis
Overview
Authors
Affiliations
Background: There is scant evidence to support target drug exposures for optimal tuberculosis outcomes. We therefore assessed whether pharmacokinetic/pharmacodynamic (PK/PD) parameters could predict 2-month culture conversion.
Methods: One hundred patients with pulmonary tuberculosis (65% human immunodeficiency virus coinfected) were intensively sampled to determine rifampicin, isoniazid, and pyrazinamide plasma concentrations after 7-8 weeks of therapy, and PK parameters determined using nonlinear mixed-effects models. Detailed clinical data and sputum for culture were collected at baseline, 2 months, and 5-6 months. Minimum inhibitory concentrations (MICs) were determined on baseline isolates. Multivariate logistic regression and the assumption-free multivariate adaptive regression splines (MARS) were used to identify clinical and PK/PD predictors of 2-month culture conversion. Potential PK/PD predictors included 0- to 24-hour area under the curve (AUC0-24), maximum concentration (Cmax), AUC0-24/MIC, Cmax/MIC, and percentage of time that concentrations persisted above the MIC (%TMIC).
Results: Twenty-six percent of patients had Cmax of rifampicin <8 mg/L, pyrazinamide <35 mg/L, and isoniazid <3 mg/L. No relationship was found between PK exposures and 2-month culture conversion using multivariate logistic regression after adjusting for MIC. However, MARS identified negative interactions between isoniazid Cmax and rifampicin Cmax/MIC ratio on 2-month culture conversion. If isoniazid Cmax was <4.6 mg/L and rifampicin Cmax/MIC <28, the isoniazid concentration had an antagonistic effect on culture conversion. For patients with isoniazid Cmax >4.6 mg/L, higher isoniazid exposures were associated with improved rates of culture conversion.
Conclusions: PK/PD analyses using MARS identified isoniazid Cmax and rifampicin Cmax/MIC thresholds below which there is concentration-dependent antagonism that reduces 2-month sputum culture conversion.
A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
Verma R, Da Silva K, Rockwood N, Wasmann R, Yende N, Song T Am J Respir Crit Care Med. 2024; 209(12):1486-1496.
PMID: 38647526 PMC: 11208962. DOI: 10.1164/rccm.202309-1583OC.
Yunivita V, Gafar F, Santoso P, Chaidir L, Soeroto A, Meirina T J Antimicrob Chemother. 2024; 79(5):977-986.
PMID: 38459759 PMC: 11062943. DOI: 10.1093/jac/dkae057.
Beraldi-Magalhaes F, Parker S, Sanches C, Garcia L, Souza Carvalho B, Costa A Trop Med Infect Dis. 2023; 8(6).
PMID: 37368730 PMC: 10303681. DOI: 10.3390/tropicalmed8060312.
Liu Y, Moodley M, Pasipanodya J, Gumbo T Antimicrob Agents Chemother. 2023; 67(4):e0140122.
PMID: 36877034 PMC: 10112185. DOI: 10.1128/aac.01401-22.
Zhang M, Wang M, He J Front Med (Lausanne). 2022; 9:822201.
PMID: 35280900 PMC: 8916538. DOI: 10.3389/fmed.2022.822201.